16 completed, 1 recruiting, 1 terminated. 10 Phase 2, 6 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
| Phase 3 | 6 | Completed 4, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
Follow dalcetrapib: new trials by email Literature Review of dalcetrapib trials Research Report on dalcetrapib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS Dalcetrapib, Placebo - Acute Coronary Syndrome | Phase 3 | Recruiting | DalCor Pharmaceuticals | 2000 | 2023-10-03 | 2026-06-22 |
| Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 Dalcetrapib, Placebo - Covid19 | Phase 2 | Completed | DalCor Pharmaceuticals | 227 | 2021-01-11 | 2022-12-07 |
| Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS dalcetrapib, Placebo - Acute Coronary Syndrome | Phase 3 | Completed | DalCor Pharmaceuticals | 6147 | 2016-04-01 | 2022-10-12 |
| A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease Background care, Placebo, dalcetrapib - Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD) | Phase 3 | Completed | Hoffmann-La Roche | 2220 | 2012-01-01 | 2016-11-02 |
| A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers dalcetrapib - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 6 | 2011-10-01 | 2019-12-17 |
| A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers atorvastatin, dalcetrapib - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 24 | 2011-06-01 | 2019-12-17 |
| A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) dalcetrapib, placebo - Coronary Heart Disease | Phase 3 | Completed | Hoffmann-La Roche | 300 | 2011-03-01 | 2019-07-30 |
| A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease Dalcetrapib, Placebo - Cardiovascular Disease | Phase 3 | Terminated | Hoffmann-La Roche | 936 | 2010-01-01 | 2020-03-24 |
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome Dalcetrapib (RO4607381), Evidence-based medical care for Acute Coronary Syndrome, Placebo - Coronary Heart Disease | Phase 3 | Completed | Hoffmann-La Roche | 15871 | 2008-04-01 | 2020-01-03 |
| A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease Dalcetrapib (RO4607381), Placebo - Coronary Heart Disease | Phase 2 | Completed | Hoffmann-La Roche | 130 | 2008-03-01 | 2020-01-03 |
| A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients Placebo, dalcetrapib - Coronary Heart Disease | Phase 2 | Completed | Hoffmann-La Roche | 476 | 2008-02-01 | 2020-01-02 |
| A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 dalcetrapib (RO4607381), placebo - Coronary Heart Disease | Phase 2 | Completed | Hoffmann-La Roche | 77 | 2007-01-01 | 2020-01-03 |
| A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent. Placebo, dalcetrapib - Coronary Heart Disease | Phase 2 | Completed | Hoffmann-La Roche | 135 | 2006-07-01 | 2020-01-27 |
| A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C) Placebo, Pravastatin, Dalcetrapib - Dyslipidemia | Phase 2 | Completed | Hoffmann-La Roche | 292 | 2005-07-01 | 2020-01-02 |
| Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels JTT-705 600 mg and simvastatin 40 mg, Placebo and simvastatin 40 mg - Dyslipidemia | Phase 2 | Completed | Akros Pharma Inc. | 92 | 2004-02-01 | 2008-06-03 |
| Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels JTT-705 600 mg and atorvastatin 20 mg, Placebo and atorvastatin 20 mg - Dyslipidemia | Phase 2 | Completed | Akros Pharma Inc. | 105 | 2004-01-01 | 2008-06-03 |
| Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia JTT-705 600 mg and pravastatin 40 mg, JTT-705 300 mg and pravastatin 40 mg, Placebo and pravastatin 40 mg - Type II Hyperlipidemia | Phase 2 | Completed | Akros Pharma Inc. | 155 | 2002-06-01 | 2008-06-03 |
| Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia Placebo, JTT-705 300mg, JTT-705 600mg - Type II Hyperlipidaemia | Phase 2 | Completed | Japan Tobacco Inc. | 198 | 2000-05-01 | 2008-05-29 |
Coronary Disease (7) · Dyslipidemias (4) · Acute Coronary Syndrome (2) · Cardiovascular Diseases (2) · Hyperlipoproteinemia Type II (2) · COVID-19 (1) · Peripheral Arterial Disease (1)
Hoffmann-La Roche (11) · Akros Pharma Inc. (3) · DalCor Pharmaceuticals (3) · Japan Tobacco Inc. (1)
Netherlands (10) · United States (10) · Canada (7) · Germany (5) · United Kingdom (5) · Czechia (4) · France (4) · Poland (4) · Switzerland (4) · Australia (3) · Austria (3) · Denmark (3) · Hungary (3) · Italy (3) · New Zealand (3)
David Kallend (1) · David Kallend, MBBS (1) · Donald M Black, MD (1)
PMID 22345126, PMID 25583994, PMID 27418594, PMID 19576325, PMID 19958854, PMID 20738227, PMID 21128879, PMID 21908036, PMID 23126252, PMID 23942908, PMID 24135322, PMID 26022813, PMID 28073769, PMID 29071331, PMID 31927126, PMID 32087417, PMID 32144166, PMID 34173811, PMID 35856777